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UtOBJECTIVES This study sought to investigate the prevalence of systolic dysfunction using global longitudinal strain
(GLS) and its prognostic value in relatives of dilated cardiomyopathy (DCM) patients that had normal left ventricular
ejection fraction (LVEF).
BACKGROUND DCM relatives are advised to undergo cardiac assessment including echocardiography, irrespective of
the genetic status of the index patient. Even though LVEF is normal, the question remains whether this indicates absence
of disease or simply normal cardiac volumes. GLS may provide additional information regarding (sub)clinical cardiac
abnormalities and thus allow earlier disease detection.
METHODS A total of 251 DCM relatives and 251 control subjects with a normal LVEF ($55%) were screened. Automated
software measured the GLS on echocardiographic 2-, 3-, and 4-chamber views. The cutoff value for abnormal strain was
>21.5. Median follow-up was 40 months (interquartile range: 5 to 80 months). Primary outcome was the combination
of death and cardiac hospitalization.
RESULTS A total of 120 relatives and 83 control subjects showed abnormal GLS (48% vs. 33%, respectively;
p < 0.001). Abnormal GLS was independently associated with DCM relatives and cardiovascular risk factors, rather than
genetic mutations. Subjects with abnormal GLS had more frequent cardiac hospitalizations and a higher mortality as
compared with subjects with normal GLS (hazard ratio: 3.29; 95% confidence interval: 1.58 to 6.87; p ¼ 0.001). Addi-
tionally, follow-up LVEF was measured in a subset of relatives, and it decreased significantly in those with abnormal as
compared with normal GLS (p ¼ 0.006).
CONCLUSIONS Relatives of DCM patients had a significantly higher prevalence of systolic dysfunction detected by GLS
despite normal LVEF compared with control subjects, independent of age, sex, comorbidities, and genotype. Abnormal
GLS was associated with LVEF deterioration, cardiac hospitalization, and death. (J Am Coll Cardiol Img 2020;13:549–58)
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550“I diopathic” dilated cardiomyopathy(DCM) is a common cause of heartfailure (HF) in young adult patients
and is frequently seen at the outpatient clinic
(1). Adequate diagnosis is important not only
for the patients but also for their family
because all relatives of DCM patients are at
risk of developing HF. Importantly, this risk
is irrespective of the particular cause or a
proven genetic mutation in the index patient
as a result of familial susceptibility (2).
Although often no causal genetic mutationsare found in DCM families, frequent cardiac screening
is advised for all first-degree relatives by the latest
position papers of the American Heart Association
and the European Society of Cardiology (to detect car-
diac abnormalities such as left ventricular enlarge-
ment or reduced left ventricular ejection fraction
(LVEF) (3–6). This constitutes a substantial propor-
tion of patients seen by the general cardiologist,
given the estimated prevalence of DCM of 1:250 to
1:500 and an average of 4 to 5 first-degree relatives
in Western countries (7). Moreover, relatives are of
different age categories, and cardiovascular risk fac-
tors accumulate with increasing age, thus potentially
influencing cardiac function irrespective of family
history.SEE PAGE 559Of course, ready identification and treatment of
disease are warranted in this group of individuals to
prevent disease progression and occurrence of
adverse cardiac events (e.g., sudden cardiac death).
However, subtle functional or structural changes of
the myocardium are likely to be missed when using
classic echocardiographic parameters such as LVEF
because ventricular volumes may be preserved or
subtle changes of LVEF may remain concealed as a
result of measurement noise in early stages of cardiac
disease (8). Global longitudinal strain (GLS) seems to
be able to detect subtle changes preceding deterio-
ration of LVEF in different HF cohorts (8). Therefore,
this study evaluated the role of GLS in asymptomatic
DCM relatives with normal LVEF to identify subtle
cardiac abnormalities and associate those findings
with distinctive clinical parameters, genotype, and
prognosis. The findings are compared with those instedt contributed equally to this work and are joint senior aut
NWE702. Drs. Schummers and Schreckenberg are both employee
d funding from the Netherlands Organization for Scientific Re
has received research support (software, hardware) from TOMTE
ave no relationships relevant to the contents of this paper to dis
received December 14, 2018; revised manuscript received Februcontrol subjects with normal LVEF and similar age,
sex, and comorbidity distribution, to be able to
investigate the true family effect in DCM relatives.
METHODS
STUDY SUBJECTS. DCM relatives. This retrospec-
tive study was carried out in a group of relatives of
genotyped DCM patients who were seen for genetic
analysis at the Maastricht University Medical Centre in
Maastricht, the Netherlands between 2009 and 2017.
Initially, pedigree analysis and sequencing of a 47
cardiomyopathy-associated gene panel was per-
formed in all index patients to determine genetic
status (Supplemental Table 1). Genetic counseling,
testing, and analysis were performed previously as
described (9). Genetic DCMwas defined as a confirmed
class 4 or 5 pathogenic mutation; a list of all patho-
genicmutations can be found in Supplemental Table 2.
All index patients were counseled to inform their
first-degree relatives about their cardiac disease and
the necessity for cardiac screening regardless of ge-
netic status. Pedigrees of 607 unrelated DCM index
patients were retrospectively analyzed. In total, 333
relatives from 158 different families were seen in our
hospital for cardiac screening, which consisted of
medical history, physical examination, electrocardi-
ography, and echocardiography. Only first-degree
relatives with a completely normal LVEF ($55%)
were included for analysis (10) (Figure 1). The study
was performed according to the Declaration of Hel-
sinki and was approved by the Medical Ethics Com-
mittee of Maastricht University Medical Centre
(METC 16-4-222).
Control subjects. Control subjects were selected from
the Outpatient Cardiology Clinic Registry (CVC data-
base) from the Maastricht University Medical Centre
including patients referred for chest pain, dyspnea, or
palpitations between April 2006 and February 2008.
Cardiac screening included physical examination,
electrocardiography, and echocardiography. A total of
1,610 of 2,110 patients demonstrated normal LVEF
($55%) on echocardiography. Control patients were
randomly selected from these 1,610 patients. A cohort
of 251 control subjects was selected from the outpa-
tient database with similar age, sex, and comorbidityhors. Dr. Eurlings has received grant support from
s at TOMTEC Imaging Systems, GmbH. Dr. Lumens
search (NWO-ZonMw, VIDI grant 016.176.340). Dr.
C Imaging Systems. All other authors have reported
close.
ary 23, 2019, accepted February 28, 2019.
FIGURE 1 Flowchart of Patient Selection
Relatives who underwent
cardiac screening
N = 333
CVC database
N = 1,610
LVEF >54%
N = 251
Abnormal GLS
N = 120 (48%)
Genetic mutation
N = 13 (10%)
Genetic mutation
N = 18 (15%)
Normal GLS
N = 131 (52%)
Abnormal GLS
N = 83 (33%)
Normal GLS
N = 168 (67%)
LVEF >54%
N = 251
1:1 Matching
Echocardiograms of 333 relatives were available at our center. Eventually, 251 patients had a normal left ventricular ejection fraction (LVEF)
($55%) and an echocardiogram, which was suitable for analysis of global longitudinal strain (GLS). These 251 relatives had no significant
differences in baseline characteristics compared with a control cohort of 251 control subjects. CVC ¼ Outpatient Cardiology Clinic Registry.
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551distribution (hypertension, diabetes, atrial fibrilla-
tion, coronary artery disease [CAD]).
ECHOCARDIOGRAPHIC PROTOCOL. All echocardio-
graphic images were made during clinical routine
using a Philips IE33 ultrasound system (Philips,
Eindhoven, the Netherlands) obtaining standard
parasternal, apical, and subcostal views according to
current recommendations (10). Standard measure-
ments were retrieved from the clinical echocardio-
graphic database including cardiac dimensions, LVEF
using Simpson’s method, and presence of any rele-
vant valve disease (11). Still, a minority of patients
had only evaluation of LVEF by the Teichholz method
(n ¼ 67; 13.3%).
In addition to the existing measurements, analysis
of left ventricular function with speckle tracking–
based GLS was performed, applying a dedicated
software package (AutoSTRAIN, TOMTEC-ARENA*
1.2, TOMTEC Imaging Systems GmbH, Unters-
chleissheim, Germany) with a recently published al-
gorithm (12). Briefly, apical 2-, 3- and 4-chamber
views of all patients were uploaded onto a computer.
Three experienced physicians reviewed all echocar-
diograms for image quality and completeness (C.K.,
J.M., J.V.). Incomplete echocardiograms or studies of
insufficient quality were not taken into consideration
for analysis. The user was requested to indicate the
correct loops to the software. Regional and global
longitudinal peak systolic strain was calculated
applying a contour detection algorithm. Furthermore,the contours suggested by the automated software
were revised and corrected if deemed necessary by 4
independent investigators (C.K., J.M., J.V., J.W.). For
this analysis, we used a vendor-specific cutoff value
of 21.5 to define abnormal GLS, as previously
described (13).
FOLLOW-UP. Minimum follow-up duration after the
first outpatient visit was 1 month, and follow-up
ranged up to 8 years. Total median follow-up of the
whole cohort was 40 months (interquartile range: 5 to
80 months). Follow-up data on death and cardiac
hospitalization were collected using medical records.
The primary outcome endpoint was the combination
of death and cardiac hospitalization.
In addition to baseline measurement, 69 DCM rel-
atives (27.5%) with a normal LVEF at baseline un-
derwent echocardiography during follow-up. LVEF
deterioration was defined as an LVEF <55% with a
minimal decrease of 5% at follow-up.
STATISTICAL ANALYSIS. Data are presented as fre-
quencies, mean  SD, or median (interquartile range).
Comparisons between groups were performed using
chi-square tests for categorical data and Student’s
t-test or Mann-Whitney U test for continuous data, as
appropriate. The Kruskal-Wallis test was used to analyze
and to compare continuous data among 3 groups.
Univariable and multivariable regression analysis
with a generalized estimating equations (GEE)
approach in a binomial model was performed to test
the association between clinical parameters and
TABLE 1 Baseline Characteristics of the DCM Relatives and Control Subjects
DCM Relatives
(n ¼ 251)
Control Subjects
(n ¼ 251) p Value
Male 113 (45) 129 (51) 0.15
Age (yrs) 46  17 46  13 0.65
Body mass index (kg/m2) 26  4 26  5 0.7
NYHA functional class III–IV 8 (3) 16 (6) 0.09
cLBBB 6 (2) 15 (6) 0.07
Chemotherapy 7 (3) 16 (6) 0.13
Genetic status
Familial DCM 126 (50) 0 (0) <0.001
Relative of index with mutation 61 (24) 0 (0) <0.001
Familial gene mutation present 31 (12) 0 (0) <0.001
Cardiovascular history
Coronary artery disease 14 (6) 7 (3) 0.11
Stroke 6 (2) 2 (1) 0.17
CABG 3 (1) 0 (0) 0.12
PCI 6 (2) 5 (2) 0.74
Valvular disease 42 (17) 49 (20) 0.42
Comorbidities
Atrial fibrillation 2 (1) 4 (2) 4 (2)
Hypertension 65 (26) 57 (23) 57 (23)
COPD 10 (4) 13 (5) 13 (5)
Hypercholesterolemia 30 (12) 44 (18) 44 (18)
Diabetes mellitus 21 (8) 15 (6) 15 (6)
Medication
Beta-blocker 29 (12) 45 (18) 0.33
ACE inhibitor 17 (7) 19 (8) 0.73
ARB 18 (7) 24 (10) 0.84
MRA 2 (1) 1 (0) 0.59
Diuretics 17 (7) 13 (5) 13 (5)
Calcium antagonists 11 (4) 22 (9) 22 (9)
Statins 37 (15) 44 (18) 44 (18)
Values are n (%) or mean  SD.
ACE ¼ angiotensin-converting enzyme; ARB¼ angiotensin II receptor blocker; CABG¼ coronary
artery bypass grafting; cLBBB ¼ complete left bundle branch block; COPD ¼ chronic obstructive
pulmonary disease; DCM ¼ dilated cardiomyopathy; MRA ¼ mineralocorticoid receptor antago-
nist; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention.
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552abnormal GLS in the total cohort (n ¼ 502). A GEE
approach was performed with an exchangeable cor-
relation structure to adjust for correlated observa-
tions within families because there are large families
with multiple first-degree relatives included in the
DCM relatives cohort. For multivariable analysis, we
first included all parameters with a cutoff for entry of
p < 0.10 in the univariable analysis. The final multi-
variable model was created by backward elimination
with a cutoff of p > 0.05.
To assess which clinical variables influenced the
progression of LVEF in a longitudinal fashion, uni-
variate analysis was performed using GEE in a subset
of study cohort with multiple echoes (n ¼ 69). Uni-
variable Cox proportional hazards regression analysis
was performed to assess clinical and demographic
covariates associated event-free survival. The level of
significance was p < 0.05, and tests were 2-sided.Calculations were done using SPSS software version
23.0 (IBM Corp., Armonk, New York), and R environ-
ment version 3.5 (R Foundation, Vienna, Austria).
RESULTS
Baseline characteristics of the study and control
group did not show significant differences (Tables 1
and 2). A total of 120 DCM relatives (48%) compared
with 83 healthy control subjects (33%) had an
abnormal GLS despite having a normal LVEF and
volumetric parameters (p < 0.001) (Figure 1, Supple-
mental Table 3).
GENETIC STATUS OF DCM RELATIVES. A total of 41
(26%) of the 158 index DCM patients, used for the
selection of DCM relatives, had a genetic mutation,
with predominantly TTN and LMNA mutations (Sup-
plemental Table 2). In total, 92 (28%) of the 333 rela-
tives who underwent cardiac screening were related
to these 41 DCM index patients with a genetic muta-
tion (Supplemental Figure 1). Thus, the majority of
the DCM relatives who underwent cardiac screening
were related to DCM index patients without a proven
genetic mutation, reflecting typical daily practice.
DCM relatives with an LVEF <55% at baseline were
excluded, showing no significant difference in patient
selection between DCM relatives related to mutation-
positive as compared with mutation-negative DCM
index patients (30% vs. 21%; p ¼ 0.07) (Supplemental
Figure 1). In total, 44 DCM relatives of mutation-
positive DCM index patients underwent genetic
testing: 32 carriers and 12 without the familial muta-
tion (Supplemental Table 2).
GLS DIFFERENCE BETWEEN DCM RELATIVES AND
CONTROL SUBJECTS. The absolute GLS value in
DCM relatives was worse compared with the control
group (21.6 [interquartile range (IQR): 19 to 24]
vs. 23.1 [IQR: 21 to 26], respectively; p < 0.001)
(Figure 2A, Table 2). Importantly, DCM relatives with a
genetic mutation had a significant worse absolute GLS
value as compared with relatives without a genetic
mutation and control subjects (20.1 [IQR: 18 to 23]
vs. 21.7 [IQR: 20 to 24] vs. 23.1 [IQR: 21 to 26],
respectively; Kruskal-Wallis p < 0.001) (Figure 2B).
CLINICAL PARAMETERS INFLUENCING GLS. All
clinical factors associated with abnormal GLS in uni-
variable analysis are depicted in Table 3. Importantly,
in the multivariable regression analysis with GEE
approach, male sex, increased age, chemotherapy,
CAD, chronic obstructive pulmonary disease, and
status as a DCM relative remained independent fac-
tors associated with abnormal GLS (Table 3). Inter-
estingly, a DCM relative had a 2-fold increased risk of
TABLE 2 Echocardiographic Baseline Parameters of the DCM Relatives and
Control Subjects
DCM Relatives
(n ¼ 251)
Control Subjects
(n ¼ 251) p Value
Systolic function
LVEF (%) 61  3.8 61  3.9 0.23
LVEDD (mm) 49  4.9 49  4.7 0.15
LVESD (mm) 33  3.6 33  3.7 0.06
IVS (mm) 8  1.8 8  1.2 0.36
PWT (mm) 8  1.3 8  1.1 0.10
LA volume index (ml/m2) 33  10.6 31  8.5 0.49
GLS (%) 21.6 (19 to 24) 23.1 (21 to 26) <0.001
Abnormal GLS 120 (48) 83 (33) 0.001
Diastolic function
E/A ratio 1.2  0.4 1.3  0.4 0.07
TI velocity (cm/s) 2.2  0.3 2.3  0.4 0.10
Values are mean  SD, median (interquartile range), or n (%).
DCM¼ dilated cardiomyopathy; GLS¼ global longitudinal strain; IVS¼ interventricular septum;
LA ¼ left atrium; LVEDD ¼ left ventricular end-diastolic diameter; LVEF ¼ left ventricular ejection
fraction; LVESD ¼ left ventricular end-systolic diameter; PWT ¼ posterior wall; TI ¼ time integral.
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553an abnormal GLS compared with the nonrelated
control subjects after correcting for sex, age, and
comorbidities (odds ratio: 2.25; 95% confidence in-
terval: 1.51 to 3.35; p < 0.001) (Central Illustration).
ABNORMAL GLS IS ASSOCIATED WITH LVEF DETE-
RIORATION IN DCM RELATIVES. Follow-up echocar-
diograms were available in 69 DCM relatives (26
normal GLS; 43 abnormal GLS) (Supplemental
Table 4). Relatives with a follow-up echo were more
often related to an index patient with a genetic mu-
tation or were carrier of a genetic mutation them-
selves. Moreover, CAD and valvular disease were
more prevalent in these relatives with a follow-up
echo (Supplemental Tables 5 and 6).
There was a median time span of 36 months
(interquartile range: 24 to 63 months) between base-
line and follow-up echocardiograms that did not
differ between the 2 groups (DCM relatives with
normal GLS vs. abnormal GLS) (p ¼ 0.99). Patients
with an abnormal GLS showed a significant decrease
in LVEF over time (60  0.6% to 56  1.1%; p ¼ 0.006)
in contrast to patients with a normal GLS at baseline
(61  0.7% to 60  0.9%; p ¼ 0.22) (Figure 3A).
Moreover, relatives with an abnormal GLS more
frequently had an abnormal LVEF (<55%) at follow-
up compared with relatives with a normal GLS (17
[40%] vs. 3 [12%]; p ¼ 0.013, respectively) (Figure 3B).
An abnormal GLS at baseline was associated with
an LVEF decrease over time using GEE analysis
(2.71%; 95% confidence interval [CI]: 4.4 to 1.03;
p ¼ 0.002) (Table 4).
DETRIMENTAL LONG-TERM PROGNOSIS IN DCM
RELATIVES WITH AN ABNORMAL GLS AT BASELINE.
An abnormal GLS at baseline resulted in a worse
event-free survival as compared with subjects with a
normal GLS in DCM relatives (hazard ratio [HR]: 3.37;
95% CI: 1.11 to 10.2; p ¼ 0.03) (Table 5). In addition to
an abnormal GLS, age, hypercholesterolemia, CAD,
hypertension, New York Heart Association functional
class III or IV, and chemotherapy in the previous
history were all associated with a worse event-free
survival in DCM relatives.
Abnormal GLS was also associated with worse
outcome in the whole study group (n ¼ 502) including
DCM relatives and control subjects (HR: 3.29; 95% CI:
1.58 to 6.87; log rank p ¼ 0.001) (Table 5, Figure 4),
even after correcting for age (HR: 2.51; 95% CI: 1.18 to
5.33; p ¼ 0.017). In total, 17 (8%) subjects with an
abnormal baseline GLS were hospitalized for cardiac
reasons, significantly more frequently compared with
8 (3%) cardiac hospitalizations among subjects with a
normal GLS at baseline (HR: 2.84; 95% CI: 1.2 to 6.6;
p ¼ 0.015) (Supplemental Table 7). During follow-up,a total of 11 cardiovascular deaths occurred, 9 in the
subjects with an abnormal GLS (HR: 5.6; 95% CI: 1.2 to
26.2; p ¼ 0.027). There were no significant differences
in events between the control subjects and DCM rel-
atives (Supplemental Table 8).
DISCUSSION
This is the largest study investigating the use of GLS
to detect early disease stage in relatives of DCM pa-
tients with a normal LVEF in comparison with in-
dividuals without a familial background of DCM. Our
most important findings are as follows: 1) abnormal
GLS is more common in DCM relatives as compared
with control subjects; 2) abnormal GLS is mainly
influenced by classic cardiovascular risk factors and
family history of DCM instead of a proven genetic
mutation; and 3) abnormal GLS is a predictor of LVEF
deterioration, cardiac hospitalization, and death.
Overall, abnormal GLS seems to reflect systolic
dysfunction despite normal LVEF and could be of
additional value for the physician in advising DCM
relatives regarding cardiac screening frequency.
CLINICAL AND GENETIC FACTORS INFLUENCING
GLS IN DCM RELATIVES. Common cardiovascular
risk factors such as CAD influence the myocardial
tissue, subsequently reflected by an abnormal GLS
(14,15). This observation is in line with our data,
showing an independent association of sex, age, and
CAD with abnormal GLS. The Norwegian HUNT (Nord-
Trøndelag Health Study) showed a similar influence
of sex and age on the GLS values in a healthy group of
1,266 individuals (14). In general, abnormal GLS is
FIGURE 2 Absolute GLS Values in Control Subjects and DCM Relatives
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(A) Control subjects have lower absolute global longitudinal strain (GLS) compared with dilated cardiomyopathy (DCM) relatives (B) with or
without a genetic mutation. Boxes represent the median and interquartile range, whiskers are 5% to 95% range, and dots represent the
outliers. The dashed red line is the used global longitudinal strain cutoff value of 21.5. The p values indicate results of Mann-Whitney U tests
and the Kruskal-Wallis test for comparing global longitudinal strain among all 3 groups: p < 0.001.
TABLE 3 Significant
Multivariable Regress
DCM relative
Female
Age (yrs)
Body mass index (kg/m
Hypertension
Coronary artery disease
COPD
Hypercholesterolemia
Diabetes mellitus
Chemotherapy
CI ¼ confidence interval; G
Tables 1 and 2.
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554more common in men with increasing age. A novel
addition of the present study is the comparison be-
tween DCM relatives and control subjects showing
the influence of being related to a DCM patient inAbnormal GLS Associated Baseline Variables at Univariable and
ion Analysis With GEE Approach in the Whole Cohort (n ¼ 502)
Univariable Analysis Multivariable Analysis
OR 95% CI p Value OR 95% CI p Value
1.86 1.31–2.67 <0.001 2.25 1.51–3.35 <0.001
0.44 0.30–0.63 <0.001 0.39 0.26–0.58 <0.001
1.04 1.02–1.05 <0.001 1.03 1.02–1.05 <0.001
2) 1.07 1.03–1.12 <0.001 — — —
2.89 1.91–4.37 <0.001 — — —
6.72 2.40–18.78 <0.001 3.47 1.33–9.05 0.011
2.92 1.21–7.02 0.02 3.40 1.38–8.38 0.008
1.95 1.20–3.17 0.007 — — —
3.66 1.81–7.37 <0.001 — — —
2.94 1.26–6.87 0.013 2.88 1.10–7.55 0.032
EE ¼ generalized estimating equations; OR ¼ odds ratio; other abbreviations as inaddition to clinical factors. This indicates a certain
genetic susceptibility in DCM relatives, which is likely
to be more complex than the current monogenetic
dogma.
We found 31 DCM relatives with a genetic mutation
but no strong correlation with GLS after multivariable
correction, although DCM relatives with a genetic
mutation had a significantly worse absolute GLS
value. A decrease in absolute GLS was previously
shown in a cohort of relatives with sarcomeric mu-
tations (MYH7, TPM1, and TNNT2), a finding indi-
cating early subtle abnormalities in myocardial
function in gene mutation carriers (16). Similar results
have been recently shown in mutation-positive DCM
relatives (17). However, those previous studies
mainly focused on DCM relatives with a proven ge-
netic mutation. Given that only w20% to 25% of DCM
patients have a proven genetic mutation after
extensive genetic screening, these relatives consti-
tute only a minority of the subjects referred for car-
diac screening (18). Therefore, our study mirrors
CENTRAL ILLUSTRATION Global Longitudinal Strain Analysis in the Screening of
Asymptomatic Relatives With Dilated Cardiomyopathy
Asymptomatic
DCM Relatives
Echocardiography for cardiac screening
Asymptomatic
Control Subjects
Abnormal GLS
Cardiac deterioration
Cardiac hospitalization and death
Normal LVEF
48% Abnormal GLS
p < 0.001 Normal LVEF
33% Abnormal GLS
Verdonschot, J.A.J. et al. J Am Coll Cardiol Img. 2020;13(2):549–58.
First-degree relatives of patients with dilated cardiomyopathy (DCM) are frequently seen at the outpatient clinic for cardiac screening. The left ventricular
ejection fraction (LVEF) is often normal; however, dilated cardiomyopathy relatives have a higher chance of abnormal global longitudinal strain (GLS). An
abnormal global longitudinal strain is associated with an increased risk of left ventricular ejection fraction deterioration, cardiac hospitalization, and death.
FIGURE 3 LVEF at Follow-Up Echocardiography in Relation to Baseline GLS in DCM Relatives (N ¼ 69)
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(A) Relatives with an abnormal global longitudinal strain (GLS) at baseline have a significantly lower left ventricular ejection fraction (LVEF) at follow-up
compared with relatives with a normal global longitudinal strain at baseline. (B) In addition, more patients have an abnormal left ventricular ejection
fraction (<55%) at follow-up in the group with abnormal global longitudinal strain at baseline. DCM ¼ dilated cardiomyopathy; echo ¼ echocardiogram.
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TABLE 4 Association Between Baseline Parameters and LVEF in Univariate
Models for the Subset of DCM Relatives With Follow-Up Echocardiograms in
GEE Models (N ¼ 69)
Baseline Variables
Univariable Analysis
b 95% CI p Value
Abnormal GLS 2.71 4.4 to 1.03 0.002
Coronary artery disease 4.54 7.12 to 1.95 <0.001
Diabetes mellitus 5.17 7.81 to 2.53 <0.001
The b reflects the change in % LVEF.
Abbreviations as in Tables 1 to 3.
TABLE 5 Significant
Follow-Up Using Univ
Control Subjects
Abnormal GLS
Age (yrs)
Hypercholesterolemia
Coronary artery disease
Diabetes mellitus
Hypertension
NYHA functional class I
Chemotherapy
HR ¼ hazard ratio; other a
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556clinical practice and adds significant insight into the
potential clinical relevance of abnormal GLS in sub-
jects referred for cardiac screening (i.e., DCM rela-
tives with normal LVEF, irrespective of proven
genetic mutations), and it highlights the need for
cardiac screening in all first-degree DCM relatives.
This is further exemplified by another small study
showing reduced absolute GLS values in a cohort of
first-degree DCM relatives when compared with con-
trol subjects (19).
PROGNOSTIC VALUE OF GLS. Our study indicates
that abnormal GLS seems to be a predictor of LVEF
deterioration, cardiac hospitalization, and death in
DCM relatives. GLS as a predictor of LVEF deteriora-
tion in DCM relatives builds on knowledge of other
forms of HF. An abnormal GLS is the most important
marker for LVEF deterioration in patients with HF
and a recovered LVEF, whereas a normal GLS pre-
dicted stable LVEF during follow-up (20). In addition,
an abnormal GLS is a strong predictor of LVEF dete-
rioration in patients receiving cardiotoxic chemo-
therapy (21). Our study adds another important group
in which GLS may be an appropriate tool for early
disease detection (22).Baseline Parameters Associated With Long-Term Outcome at
ariable Cox Regression Analysis in DCM Relatives and
Long-Term Outcome
DCM Relatives (n ¼ 251) Total Cohort (n ¼ 502)
HR 95% CI p Value HR 95% CI p Value
3.37 1.11–10.2 0.03 3.29 1.58–6.87 0.001
1.07 1.03–1.11 <0.001 1.05 1.02–1.07 <0.001
3.36 1.26–8.99 0.02 — — —
10.54 4.06–27.3 <0.001 5.83 2.64–12.8 <0.001
— — — 2.62 1.14–6.01 0.02
5.08 1.91–13.5 0.001 2.62 1.35–5.09 0.004
II to IV 6.05 1.68–21.79 0.006 2.95 1.14–7.61 0.03
5.75 1.59–20.8 0.008 3.48 1.43–8.46 0.006
bbreviations as in Tables 1 to 3.To date, studies using the prognostic value of GLS
in DCM relatives are lacking. We found that abnormal
GLS is associated with a higher risk for cardiac hos-
pitalization and death at follow-up both in this group
and in control subjects with normal LVEF. The latter
is in line with previous findings. Thus, a Norwegian
population-based study with healthy subjects
without cardiovascular disease or diabetes showed an
independent prognostic value of GLS on long-term
risk of cardiovascular morbidity and mortality, with
a median follow-up of 11 years (23). Furthermore,
there is strong evidence of the prognostic value of
GLS, which appears to have prognostic value superior
to that of LVEF in predicting death and HF hospital-
ization in patients with different forms of HF (24–26).
Prognostic data on GLS specifically in DCM patients
are mainly available from cardiac magnetic
resonance–derived feature tracking GLS, which ap-
pears to be an independent predictor of mortality
(27,28). Data on echocardiographically derived GLS
prognostic value in DCM are scarce, with only 1 study
showing GLS to be a predictor of ventricular ar-
rhythmias (29). Our study also shows the prognostic
value of abnormal GLS in otherwise healthy relatives
of DCM patients with normal LVEF.
POTENTIAL CLINICAL IMPLICATIONS. Identifying and
treating DCM relatives, who are at risk of developing
DCM, at an early stage could minimize the risk of
cardiac deterioration, hospitalization, and death (30).
Current guidelines stratify patients into having defi-
nite, probable, or possible disease according to their
genetic and clinical status (18). However, the genetic
status is not always known, and echocardiographic
screening results are often normal using classic pa-
rameters. When genetic information is not available,
the current European Society of Cardiology position
statement advises systematic cardiac screening every
2 to 5 years until the age of 60 to 65 years in first-
degree relatives of DCM patients (4). The American
Heart Association guidelines are less stringent: the
treating physician can decide to perform periodic
echocardiographic screening (6). When an asymp-
tomatic relative carries a pathogenic mutation,
repeated cardiac evaluation should be performed
every 1 to 3 years according to the European Society
of Cardiology guidelines and every 3 to 5 years ac-
cording to the American Heart Association guidelines
(6). As reflected by this lack of consensus between the
European and American guidelines, the level of evi-
dence regarding echocardiographic screening of DCM
relatives and determining their subsequent follow-up
periods is low. On the basis of our findings, classic
echocardiographic measurements could be enriched
FIGURE 4 Baseline GLS Value and Long-Term Outcome in the Whole Cohort (N ¼ 502)
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Subjects with an abnormal global longitudinal strain (GLS) at baseline have an increased
risk for cardiac hospitalization and death.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Asymptomatic
first-degree relatives of DCM patients have a higher chance of
systolic dysfunction compared with nonrelated asymptomatic
individuals. This is shown by an increased prevalence of abnormal
GLS in DCM relatives, a subtle marker for systolic dysfunction
predicting worse outcome.
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Evaluation of GLS in asymptomatic patients may have
prognostic implications even when cardiac volumes are normal.
Therefore, GLS should be obtained in addition to echocardio-
graphic volumes.
TRANSLATIONAL OUTLOOK: The inclusion of GLS analysis in
the screening of DCM relatives should be validated in larger
cohorts to better illustrate the definite role and the cost-
effectiveness of GLS in clinical decision making. Those ap-
proaches should be compared with the current guidelines for
screening of DCM relatives.
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557by determination of GLS in all DCM relatives.
Furthermore, cardiac follow-up could be extended,
with a longer interval when GLS is normal. Although
there is accumulating evidence for GLS as a marker of
subtle early disease, clinical decision making on the
basis of GLS should be further determined in a pro-
spective manner to evaluate its usefulness in pre-
dicting cardiac deterioration or onset of disease.
When investigating the clinical value of GLS, it also
needs to be considered whether starting medical
treatment early (i.e., angiotensin-converting enzyme
inhibitors) in these relatives with abnormal GLS may
improve outcome.
STUDY LIMITATIONS. This study represents a single-
center, retrospective data analysis. A prospective
multicenter study will be needed to investigate
whether clinical decision making on the basis of GLS
is safe and more cost-effective compared with the
current recommendations. We were unable to include
all relatives from all families because of the voluntary
character of the screening. In addition, indications for
follow-up echocardiography depended on clinical
background, current guidelines, and treating cardi-
ologist; therefore, a certain selection bias cannot be
excluded. This indicates that many relatives of DCM
patients do not undergo cardiac screening, for many
reasons. Given the relatively low event rate and
available follow-up echocardiograms, the current
study had insufficient power to perform multivariable
modeling to test for independent predictors of LVEF
deterioration and long-term outcome. Therefore,
these results should be interpreted with caution. The
number of asymptomatic unique mutation carriers
was relatively low in our study, thus leading to a
genetically heterogeneous group. Moreover, a 47-
gene panel was used to screen for genetic mutation
in the DCM index patients. However, we cannot
exclude the contribution of other genes to the
phenotype in the index patients and the carrier status
in their relatives.
CONCLUSIONS
Relatives of DCM patients have a higher chance of
systolic dysfunction reflected by an abnormal GLS,
independent of age, sex, comorbidities, and geno-
type. An abnormal GLS is associated with LVEF
deterioration, cardiac hospitalization, and death in
asymptomatic DCM relatives with normal LVEF. GLS
seems to be a promising tool for cardiac screening of
relatives and could be used to identify patients at risk
for adverse events who will benefit most from regular
follow-up and treatment.ADDRESS FOR CORRESPONDENCE: Dr. Christian Knack-
stedt, Department of Cardiology, Maastricht Universitair
Medisch Centrumþ, P.O. Box 5800, 6202 AZ Maastricht,
the Netherlands. E-mail: c.knackstedt@mumc.nl.
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